Hospira S.p.A.
Form 483 issued May 13, 2014 · Liscate, Italy
- Observations
- 10
- Pages
- 7
- FEI number
- 3004640070
In short: On May 13, 2014, FDA issued a Form 483 with 10 observations to Hospira S.p.A. in Liscate, Italy (FEI 3004640070). Most observations concern facilities & equipment and laboratory controls; the most-cited regulation is 21 CFR 211.42 (design and construction features).
At a glance
Facilities & equipment and laboratory controls account for 8 of 10 observations.
What FDA observed
Preview: the opening words of each observationDashed: section inferred by FDA Intel and checked against the regulation text
- 01
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include…
- 02
Appropriate controls are not exercised over computers or related systems to assure that changes in master…
- 03
Observation 3: scanned text, readable in the full document.
- 04
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment…
This inspection in context
Questions about this 483
What did FDA find at Hospira S.p.A.?
FDA listed 10 observations on this Form 483, mostly about facilities & equipment, laboratory controls and production. The most-cited regulation is 21 CFR 211.42 (design and construction features). The opening words of each observation are shown on this page.
When was Hospira S.p.A. inspected by FDA?
This Form 483 is dated May 13, 2014.
How do I get the full Form 483 for Hospira S.p.A.?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.